-
Revenue: Q4 revenue of $0.3 million, a significant decrease from $1.6 million in Q4 2022, falling short of the estimated $1.4 million.
-
Net Loss: Q4 net loss widened to $23.5 million from $19.5 million year-over-year, surpassing the estimated net loss of $20.85 million.
-
Research and Development: R&D expenses increased slightly to $12.3 million in Q4 2023 from $11.3 million in the same period last year.
-
Administrative Expenses: Selling, general, and administrative expenses rose to $9.3 million in Q4 2023, up from $7.7 million in Q4 2022.
-
Liquidity Position: Cash, cash equivalents, and short-term investments totaled $97.7 million as of December 31, 2023.
-
Forward Guidance: Absci believes its funds will be sufficient to support operations into the first half of 2027, with an anticipated gross use of cash of approximately $80 million for the fiscal year 2024.
On March 21, 2024, Absci Corp (NASDAQ:ABSI), a trailblazer in AI-driven biologic drug discovery, disclosed its financial and operating results for the fourth quarter and full year of 2023 through its 8-K filing. Despite the companys strategic advancements and collaborations, the reported figures revealed a shortfall in revenue and an increase in net loss compared to the previous year.
Absci Corp is a data-first generative AI drug creation company that aims to revolutionize the creation of novel biologics, merging drug discovery and cell line development processes. Its innovative approach promises to expedite the delivery of new therapeutics to patients.
Financial Performance and Challenges
The company's revenue for the fourth quarter of 2023 was $0.3 million, a stark decrease from the $1.6 million reported in the same quarter of the previous year, and below the analyst's estimate of $1.4 million. The full-year revenue remained flat at $5.7 million. The decrease in quarterly revenue was attributed to the mix of partnered and internal programs and their progress.
Research and development expenses for the fourth quarter edged up to $12.3 million, while selling, general, and administrative expenses increased to $9.3 million, reflecting a rise in stock compensation expense. These investments indicate Absci's commitment to its AI-driven platform and drug discovery programs but also underscore the financial pressures of advancing such cutting-edge technology.
The net loss for the fourth quarter widened to $23.5 million from $19.5 million in the prior-year period, exceeding the estimated net loss of $20.85 million. The full-year net loss also grew to $110.6 million from $104.9 million in the previous year. This trend underscores the challenges Absci faces in controlling expenses while striving to innovate in the competitive biotechnology industry.